Deregulated expression of G1 cyclins and their cognate cdk partners is often found in human tumor cells.
2
These findings argue against the proposed necessity of complete Rb inactivation by sequential phosphorylation by D- and E-type cyclin-cdk complexes.
3
We have studied the role of a conserved hydrophobic patch on the surface of cyclin A in substrate recognition by cyclin A-cdk2.
4
In addition, the concomitant expression of Np95 and of cycE-cdk2 was alone sufficient to induce S phase in TD cells.
5
Shortening of G1 phase temporally correlated with more rapid degradation of the cdk inhibitor p27Kip1 and with premature activation of cyclin A-dependent cdk2.
Ús de cyclin-dependent kinase en anglès
1
Purpose: Flavopiridol is the first cyclin-dependentkinase inhibitor to enter clinical trials.
2
The results implicate a putative cyclin-dependentkinase in the control of development.
3
The other three mutants caused phenotypes dependent on the particular cyclin-dependentkinase.
4
Cdc2 is the cyclin-dependentkinase that controls entry of cells into mitosis.
5
D-type cyclin-dependentkinase activities have not so far been detected in mammalian cells.
6
A major determinant of Acm1 stability is phosphorylation at consensus cyclin-dependentkinase sites.
7
Finally, the effects of cyclin-dependentkinase inhibitors on dihydrofolate reductase gene expression were evaluated.
8
The expression of cyclin-dependentkinase inhibitor p21 is dramatically increased in the mutant embryos.
9
CF neutrophils formed more NETs and this was reversed by cyclin-dependentkinase inhibitor exposure.
10
Purpose: Flavopiridol is a cyclin-dependentkinase inhibitor that prevents cell cycle progression and tumor growth.
11
Interestingly, this response was self-limited at later developmental time points by an upregulation of the cyclin-dependentkinase inhibitor p21.
12
Despite its partial structural similarity with the cyclins, p25 displays an unprecedented mechanism for the regulation of a cyclin-dependentkinase.
13
The expression of the transcription factor Sp1, a retinoblastoma-interacting protein, was also enhanced by all the cyclin-dependentkinase inhibitors tested.
14
These compounds exhibited potent inhibitory activity against cyclin-dependentkinase 4 and good antiproliferative activity in a human colon carcinoma cell line.
15
Ibrance works by blocking two enzymes, cyclin-dependentkinase 4 and 6, that are involved in cell growth.
16
Treatment with the cyclin-dependentkinase inhibitor SCH727965 alone or in combination is a highly promising novel experimental therapeutic strategy against pancreatic cancer.